Benitec Biopharma appoints David Friedman to board; Megan Boston resigns as director but remains CFO

Benitec Biopharma Inc.

David Friedman joined board as Class III director effective May 22, 2026; term until 2028 annual meeting.
Friedman granted options to purchase 35,000 shares at closing price on May 26, 2026; vesting by next annual meeting or 1 year.
Megan Boston resigned from board effective May 22, 2026; continues as CFO and secretary; no dispute.
Friedman entitled to standard non-employee director compensation; will enter indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Megan Boston

Director

BNTC · Benitec Biopharma Inc.

Effective: 2026-05-22
Filed: May 29, 2026, 4:10 PM ET

On May 22, 2026, Megan Boston, the Company’s chief financial officer and secretary and a member of the Board since 2016, notified the Board of her decision to resign solely from the Board and rotated off the Board as part of the Company’s ongoing Board composition and governance review.

Appointed

David Friedman

Director

BNTC · Benitec Biopharma Inc.

Effective: 2026-05-22
Filed: May 29, 2026, 4:10 PM ET

On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Megan Boston resigned as Director at Benitec Biopharma Inc..

Action: resigned
Role: Director

Exact text from the filing

On May 22, 2026, Megan Boston, the Company’s chief financial officer and secretary and a member of the Board since 2016, notified the Board of her decision to resign solely from the Board and rotated off the Board as part of the Company’s ongoing Board composition and governance review.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Friedman was appointed as Director at Benitec Biopharma Inc..

Action: appointed
Role: Director

Exact text from the filing

On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date.

View on SEC.gov

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-248289

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.